Speaker

Guido Kroemer is currently Professor at the Faculty of Medicine of the University of Paris, Director of the research team "Metabolism, Cancer and Immunity" of the French Medical Research Council (INSERM), Director of the Metabolomics and Cell Biology platforms of the Gustave Roussy Comprehensive Cancer Center, and Hospital Practitioner at the Hôpital Européen George Pompidou, Paris, France. Dr. Kroemer’s work focuses on the pathophysiological implications of cell stress and death in the context of aging, cancer and inflammation. With over 1600 articles including 67 papers in the ‘CNS’ Journals Cell (15 papers), Nature (6), Nature Medicine (21), Science (18) and Science Translational Medicine (7) and an h-index of 288, he is Europe’s most cited researcher in biomedical research. His contributions have been recognized with multiple awards including the most prestigious cancer research and immunology prizes from Belgium (Baillet-Latour Health Prize), France (Prix Duquesne, Prix Léopold Griffuel, Grand Prix Ruban Rose), Spain (International Prize for Oncology Ramiro Carregal, Boulle-SEI Award) and Switzerland (Brupbacher Prize), the European Union-sponsored Descartes Prize, as well as the most important Italian science prize (Lombardia & Ricerca Prize). He also received two European Research Council (ERC) Advanced Investigator Awards. Kroemer is the founding Editor-in-Chief of six journals: Cell Death & Disease, Cell Stress, OncoImmunology, MedComm Cancer, Microbial Cell, and Molecular & Cellular Oncology. He is member of the Austrian Academy of Sciences, Academia Europaea, European Academy of Sciences (EAS), Chinese Academy of Engineering (CAE), European Academy of Sciences and Arts (EASA), European Academy of Cancer Sciences (EACS), European Molecular Biology Organization (EMBO), German Academy of Sciences (Leopoldina), Institut Universitaire de France (IUF) and Spanish Royal Academy of Sciences. He is the Founding President of the European Academy of Tumor Immunology (EATI), as well as the President-Elect of the European Network for Cancer Immunotherapy (ENCI).

« Go Back